FOLH1 and prostate carcinoma: PSMA is a transmembrane glycoprotein highly expressed in prostate cancer, and several PSMA-targeted radiopharmaceuticals have been developed for imaging (PET and SPECT) and treatment of prostate cancer [75,76,77].